Skip to main content

Advertisement

Log in

Biotech’s baby boom

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

A Publisher Correction to this article was published on 18 June 2019

This article has been updated

2018 was the year when the funding machine for privately held biotech companies went into overdrive, with mega-rounds and rapid flotations. John Hodgson brings us this deep dive.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Global amount and number of financings raised by venture capital funds, 2007–2018.
Fig. 2: Average amount venture capital raised per round in the United States, Europe and China, 2014–2018.
Fig. 3: The evolution of the A round.
Fig. 4: $100-million-plus round evolution.
Fig. 5: Private biotech company exits.
Fig. 6: Biotech is not special.

Change history

  • 18 June 2019

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John Hodgson.

Integrated supplementary information

Supplementary Figure 1 Private biotech company exits.

a, Nasdaq Biotechnology Index (annual mean), 2009–2018. b, IPOs and M&As, 2010–2018. Source: Dow Jones VentureSource, Nasdaq.

Supplementary information

Supplementary Information

Supplementary Figure 1

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hodgson, J. Biotech’s baby boom. Nat Biotechnol 37, 502–512 (2019). https://doi.org/10.1038/s41587-019-0112-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-019-0112-4

  • Springer Nature America, Inc.

This article is cited by

Navigation